קלופידוגרל טבע ישראל - עברית - Ministry of Health

קלופידוגרל טבע

teva pharmaceutical industries ltd, israel - clopidogrel as bisulfate - טבליה - clopidogrel as bisulfate 75 mg - clopidogrel - clopidogrel - clopidogrel is indicated for the prevention of atherothrombotic events as follows : * recent mi recent stroke or established peripheral arterial disease : - patients suffering from myocardial infarction (from a few days until less than 35 days ) - ischaemic stroke ( from 7 days until less than 6 months) or established peripheral arterial disease. - for patients with a history of recent myocardial infarction (mi) recent stroke or established peripheral arterial disease - clopidogrel has been shown to reduce the rate of a combined endpoint of new ischemic stroke (fatal or not) new mi (fatal or not) and other vascular death. * acute coronary syndrome: - for patients with acute coronary syndrome [non-st segment elevation acute coronary syndrome (unstable angina/non-q-wave mi) or st segment elevation acute myocardial infarction ] in combination with asa in medically treated patients eligible for thrombolytic therapy and those who are to be managed with percutaneous coronary intervention (with or without stent) or

ברילינטה 90 מג ישראל - עברית - Ministry of Health

ברילינטה 90 מג

astrazeneca (israel) ltd - ticagrelor - טבליות מצופות פילם - ticagrelor 90 mg - ticagrelor - ticagrelor - brilinta, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndromes (unstable angina, non st elevation myocardial infarction [nstemi] or st elevation myocardial infarction [stemi]); including patients managed medically, and those who are managed with percutaneous coronary intervention (pci) or coronary artery by-pass grafting (cabg).

אריקסטרה 2.5 מג    0.5 מל ישראל - עברית - Ministry of Health

אריקסטרה 2.5 מג 0.5 מל

padagis israel agencies ltd, israel - fondaparinux sodium - תמיסה להזרקה - fondaparinux sodium 5 mg / 1 ml - fondaparinux - fondaparinux - prevention of venous thromboembolic events (vte) in adults undergoing major orthopaedic surgery of the lower limbs such as hip fracture major knee surgery or hip replacement surgery. prevention of venous thromboembolic events (vte) in adults undergoing abdominal surgery who are judged to be at high risk of thromboembolic complications such as patients undergoing abdominal cancer surgery. prevention of venous thromboembolic events (vte) in adults medical patients who are judged to be at high risk for vte and who are immobilised due to acute illness such as cardiac insufficiency and/or acute respiratory disorders and/or acute infectious or inflammatory disease. treatment of unstable angina or non-st segment elevation myocardial infarcton (ua/nstemi) in adults for whom urgent ( < 120 mins) invasive management (pci) is not indicated . treatment of st segment elevation myocardial infarction (stemi) in patients who are managed with thrombolytics or who initially are to receive no other form of reperfusion therapy.

אריקסטרה 7.5 מג  0.6 מל ישראל - עברית - Ministry of Health

אריקסטרה 7.5 מג 0.6 מל

padagis israel agencies ltd, israel - fondaparinux sodium - תמיסה להזרקה - fondaparinux sodium 12.5 mg/ml - fondaparinux - fondaparinux - treatment of adults with acute deep vein thrombosis (dvt) and treatment of acute pulmonary embolism (pe), except in haemodynamically unstable patients or patients who require thrombolysis or pulmonary embolectomy.

קסרלטו 10 מג ישראל - עברית - Ministry of Health

קסרלטו 10 מג

bayer israel ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 10 mg - rivaroxaban - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.

קסרלטו 10 מג ישראל - עברית - Ministry of Health

קסרלטו 10 מג

bayer israel ltd - rivaroxaban - טבליות מצופות פילם - rivaroxaban 10 mg - rivaroxaban - rivaroxaban - prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.

קסרלטו 15 מג ישראל - עברית - Ministry of Health

קסרלטו 15 מג

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 15 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age?75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

קסרלטו 15 מג ישראל - עברית - Ministry of Health

קסרלטו 15 מג

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 15 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age?75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

קסרלטו 20 מג ישראל - עברית - Ministry of Health

קסרלטו 20 מג

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 20 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age?75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

קסרלטו 20 מג ישראל - עברית - Ministry of Health

קסרלטו 20 מג

bayer israel ltd - rivaroxaban micronized - טבליות מצופות פילם - rivaroxaban micronized 20 mg - rivaroxaban - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age?75 years, diabetes mellitus, prior stroke or transient ischaemic attack. treatment of deep vein thrombosis (dvt),and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.